Related by context. All words. (Click for frequent words.) 70 HGS ETR1 70 perifosine 70 PXD# 68 OXi# 68 XL# XL# 68 enzastaurin 68 AP# [003] 68 XL# XL# XL# 68 MGCD# [001] 68 axitinib 68 ganetespib 67 FOLOTYN 67 PF # [001] 67 RG# [001] 67 INCB# [002] 66 Perifosine 66 Phase 1b 66 alvespimycin 66 carfilzomib 66 sapacitabine 66 Phase Ib 66 elotuzumab 66 HuMax CD4 66 lintuzumab 66 XL# XL# XL# XL# 65 forodesine 65 INCB# [001] 65 Bezielle 65 HspE7 65 pralatrexate 65 eniluracil 65 ASA# 65 IMGN# 65 OncoVEX GM CSF 65 PRT# 65 glufosfamide 64 Panzem R NCD 64 picoplatin 64 HCD# [002] 64 GRN#L 64 blinatumomab 64 Archexin 64 dacetuzumab 64 Amrubicin 64 cilengitide 64 MAXY G# 64 RDEA# 64 EndoTAG TM -1 64 volociximab 64 Carfilzomib 64 voreloxin 64 R#/MEM # 64 LymphoStat B 64 rNAPc2 64 HGS ETR2 64 antitumor activity 64 Sym# 64 IMC A# 64 Traficet EN 64 MDV# 64 CYT# 64 HuMax CD# 63 obatoclax 63 JAK inhibitor 63 Phase 2a trial 63 EOquin TM 63 ularitide 63 PEG Interferon lambda 63 HuMax EGFr 63 phase IIb clinical 63 eltrombopag 63 BCX# 63 TG# [001] 63 PEG SN# 63 tanespimycin 63 IDX# 63 orally bioavailable 63 Exelixis compounds 63 Azedra 63 BAY #-# 63 GALNS 63 tivozanib 63 SCH # 63 Proxinium TM 63 pomalidomide 63 solid tumors 63 ISIS # 63 HGS# 63 Cloretazine R VNP#M 63 romidepsin 63 ZYBRESTAT 62 phase IIa clinical 62 MGCD# [002] 62 DB# [003] 62 CR# vcMMAE 62 T DM1 62 belinostat 62 pharmacodynamic 62 vascular disrupting agent 62 Amigal 62 Phase Ib II 62 BRIM2 62 Atiprimod 62 Phase 2a 62 dose cohorts 62 PLX# 62 kinase inhibitor 62 celgosivir 62 amrubicin 62 pertuzumab 62 MAP# 62 vandetanib 62 Phase 2b study 62 AEG# 62 MEK inhibitor 62 Nuvion 62 Azixa 62 randomized discontinuation trial 62 APOPTONE 62 daclizumab 62 TG# [003] 62 TOCOSOL Paclitaxel 62 Debio 62 elesclomol 62 PLK1 SNALP 62 AQ4N 62 otelixizumab 62 talactoferrin 62 vidofludimus 62 oral prodrug 62 ADVEXIN 62 relapsed refractory multiple myeloma 62 ENMD 62 satraplatin 61 Phase 2b trial 61 EOquin 61 CCX# 61 Targretin 61 tesetaxel 61 Phase Ib clinical 61 ridaforolimus 61 XmAb# 61 CYC# 61 ozarelix 61 tamibarotene 61 ofatumumab 61 SAR# [004] 61 Apoptone 61 Pralatrexate 61 tezampanel 61 entinostat 61 teduglutide 61 PDE4 inhibitor 61 TELCYTA 61 Phase 1b trial 61 anticancer compound 61 Genasense 61 ixabepilone 61 Annamycin 61 NGX# 61 ELACYT 61 eculizumab 61 ponatinib 61 Phase 2b 61 elagolix 61 Neuradiab 61 neratinib 61 Dacogen injection 61 XL# anticancer compounds 61 MEK inhibitors 61 Daclizumab 61 dose escalation trial 61 Virulizin ® 61 HER2 positive metastatic breast 61 mapatumumab 61 phase IIa 61 MYDICAR ® 61 Azedra TM 61 deforolimus 61 ENMD # 61 RGB # 61 IMC #B 61 huC# DM4 61 dimebon 61 mipomersen 61 rindopepimut 61 atacicept 60 CoFactor 60 Xanafide 60 Zybrestat 60 epothilone 60 docetaxel Taxotere R 60 investigational humanized monoclonal antibody 60 Phase III 60 phase IIb 60 registrational trial 60 Allovectin 7 60 ongoing Phase 1b 60 RH1 60 bafetinib 60 Hsp# inhibitor 60 RP# [002] 60 metaglidasen 60 ARRY 60 AZD# 60 registrational 60 initiate Phase 1b 60 Phase Ib study 60 Phase 2a clinical 60 Phenoptin 60 Zerenex 60 Bortezomib 60 Asentar 60 oral ridaforolimus 60 PS# [001] 60 pradefovir 60 receptor tyrosine kinase inhibitor 60 BiTE antibody 60 mertansine 60 Phase IIb 60 huN# DM1 60 trastuzumab DM1 T DM1 60 FOLOTYN ® 60 bendamustine 60 YONDELIS 60 REOLYSIN ® 60 Tyrima 60 Phase IIa trials 60 hematologic malignancies 60 CUDC 60 FTY# 60 radiation sensitizer 60 Dapagliflozin 60 vosaroxin 60 HuLuc# 60 Chemophase 60 Locteron 60 Reolysin 60 preclinical 60 Aplidin 60 anti leukemic 60 BrachySil TM 60 Hsp# Inhibitor 60 Insegia 60 Epratuzumab 60 bavituximab 60 PI3K/Akt pathway inhibitor 60 preclinical studies 60 JAK2 inhibitor 60 PSMA ADC 60 hematological malignancies 60 TRX# 60 teriflunomide 60 phase Ib 60 phase 2a 60 Phase IIa clinical 60 Phase 2b clinical 60 aflibercept 60 BNC# 60 Plicera 59 seliciclib CYC# 59 CA4P 59 Enzastaurin 59 NSCLC 59 Glufosfamide 59 ulimorelin 59 Nanobody 59 multicenter Phase 59 metastatic renal cell carcinoma 59 Voreloxin 59 velafermin 59 dose cohort 59 AEZS 59 Aurexis 59 evaluating tivozanib 59 PRX # 59 MEK inhibitor RDEA# 59 protein kinase inhibitor 59 histone deacetylase HDAC inhibitor 59 DAVANAT 59 Alpharadin 59 AVN# [001] 59 Phase #b/#a 59 KRN# 59 Imprime PGG 59 AEGR 59 pan HDAC inhibitor 59 Serdaxin 59 IMA# 59 Bicifadine 59 Panzem R 59 TH# [003] 59 Cotara 59 SRT# [003] 59 UVIDEM 59 multiple ascending dose 59 ALN RSV# 59 IRX 2 59 perifosine KRX 59 JAK1 59 Alfimeprase 59 nab paclitaxel 59 Viramidine 59 Androxal TM 59 Symadex 59 Aurora kinase 59 ALN VSP 59 Tarceva erlotinib 59 pharmacokinetic PK 59 VEGF Trap 59 liposomal formulation 59 Belinostat 59 Phase III clinical 59 L BLP# 59 adecatumumab MT# 59 Phase IIb clinical 59 custirsen 59 Omacetaxine 59 laquinimod 59 Telcyta 59 tesmilifene 59 Phase 1a 59 TRIOLEX 59 GV# [001] 59 adecatumumab 59 ThermoDox ® 59 dose escalation 59 Marqibo 59 cannabinor 59 dirucotide 59 Triolex 59 BRAF inhibitor 59 favorable pharmacokinetic profile 59 NKTR 59 investigational compound 59 favorable tolerability 59 HCV protease inhibitor 59 Tanespimycin 59 angiogenesis inhibitor 59 veltuzumab 59 OvaRex R 59 decitabine 59 PEG PAL 59 OncoVEX 59 phase IIb trial 59 anticancer agent 59 farletuzumab 59 proteasome inhibitor 59 ISTODAX 59 PRX# 59 PI3K inhibitor 59 Blinatumomab 59 GATTEX 59 Phase 1b clinical 59 Phase 2b clinical trials 59 ILLUMINATE 59 sunitinib malate 59 fosbretabulin 59 iSONEP 59 eprotirome 59 Vectibix 59 ruxolitinib 59 PSN# [002] 59 trabectedin 59 sorafenib Nexavar 59 Pharmacokinetic analyzes 58 Tamibarotene 58 Mipomersen 58 docetaxel chemotherapy 58 Telaprevir 58 Phase IIb trials 58 Anticalin R 58 humanized monoclonal antibody 58 ocrelizumab 58 ProSavin 58 Satraplatin 58 erlotinib Tarceva ® 58 APD# 58 Allovectin 7 ® 58 Aflibercept 58 nonclinical studies 58 Phase #b/#a clinical 58 dose limiting toxicities 58 pharmacodynamic PD 58 Ambrisentan 58 humanized anti 58 Golimumab 58 ALN TTR 58 PNP inhibitor 58 AT# [002] 58 relapsed multiple myeloma 58 Tarceva TM 58 Neulasta ® 58 zanolimumab 58 Phase IIB 58 darapladib 58 Ocrelizumab 58 lumiliximab 58 MT# MEDI 58 ThermoDox R 58 omacetaxine 58 elacytarabine 58 refractory AML 58 cutaneous T cell 58 TELINTRA 58 Curaxin CBLC# 58 Quinamed 58 bicifadine 58 vemurafenib 58 ASONEP 58 cetrorelix 58 pivotal Phase III 58 virus HCV protease inhibitor 58 MOZOBIL 58 Cloretazine ® 58 ELND# 58 investigational monoclonal antibody 58 NVA# 58 Vitaxin 58 NXL# 58 orally administered inhibitor 58 refractory multiple myeloma 58 polymerase inhibitor 58 gefitinib 58 epratuzumab 58 Exherin TM 58 SUCCEED trial 58 Troxatyl 58 placebo controlled Phase 58 Fx #A 58 crizotinib PF # 58 Phase IIa 58 mTOR inhibitor 58 Advexin 58 OPAXIO 58 TroVax 58 PEGPH# 58 TORISEL 58 peginesatide 58 thymalfasin 58 generation purine nucleoside 58 VAPRISOL 58 Phase 1a clinical 58 Fludara 58 SNT MC# 58 tumor xenograft models 58 Ceflatonin 58 BRIM3 58 Factor VIIa 58 dose escalation Phase 58 leukemia AML 58 FLT3 58 Xcytrin 58 Aplidin R 58 ARIKACE ™ 58 LymphoStat B TM 58 panitumumab 58 DU #b 58 ON #.Na 58 tyrosine kinase inhibitor 58 castration resistant prostate cancer 58 Exelixis XL# 58 TACI Ig 58 subcutaneous formulation 58 BIBW 58 erlotinib 58 Phase IIa trial 57 seliciclib 57 Tarvacin 57 Albuferon 57 MAGE A3 ASCI 57 omecamtiv mecarbil 57 trastuzumab emtansine T DM1 57 Restanza 57 low dose cytarabine 57 ANA# 57 SUTENT 57 palifosfamide 57 INC# 57 CBLC# 57 BZL# 57 Stimuvax 57 rFVIIIFc 57 sorafenib Nexavar ® 57 TREANDA 57 PROMACTA 57 HQK 57 Virulizin R 57 Nexavar 57 CK # 57 mTOR inhibitors 57 Sapacitabine 57 randomized Phase 2b 57 Dasatinib 57 Hsp# inhibition 57 NU# [001] 57 clofarabine 57 ZD# [001] 57 linaclotide 57 Romidepsin 57 panitumumab Vectibix 57 Canvaxin TM 57 imetelstat 57 CEQ# 57 TNFerade 57 heavily pretreated patients 57 alfimeprase 57 Guanilib 57 randomized Phase 57 monotherapy 57 HDAC Inhibitor 57 Randomized Phase 57 GRN# 57 #ME# 57 selective androgen receptor modulator 57 brentuximab vedotin 57 TBC# 57 PKC# 57 investigational drug 57 Elotuzumab 57 PDX pralatrexate 57 Cethrin 57 baminercept 57 Panzem 57 bortezomib Velcade 57 depsipeptide 57 CORT # 57 alemtuzumab 57 lomitapide 57 docetaxel Taxotere ® 57 NP2 Enkephalin 57 CYT# potent vascular disrupting 57 IIa trial 57 ICA # 57 Darusentan 57 valopicitabine 57 Pimavanserin 57 Folotyn 57 INGN 57 metastatic melanoma 57 Viprinex 57 BrachySil 57 BEMA TM Fentanyl 57 CD# antibody [001] 57 OMAPRO 57 GVAX 57 oncology indications 57 Amplimexon 57 GAP #B# 57 bardoxolone 57 recurrent NSCLC 57 EGFR HER2 57 CD NP 57 Vidofludimus 57 telomerase inhibitor drug 57 Phase IIb clinical trials 57 maribavir 57 ATL# [002] 57 Prochymal 57 albinterferon alfa 2b 57 Laquinimod 57 Treanda 57 velafermin belinostat 57 CIMZIA TM 57 Phase Ib clinical trials 57 MAXY alpha 57 MyVax R 57 Synavive 57 oral Xeloda 57 class mGluR5 inhibitor 57 ispinesib 57 Nasulin 57 Virulizin 57 Genz # 57 gemcitabine Gemzar ® 57 targeting CD# 57 Vectibix monotherapy 57 Phase IIIb clinical 57 HE# [002] 57 dose escalation study 57 gallium containing 57 signal transduction inhibitor 57 Onconase 57 tafamidis 57 Ophena TM 57 R#/MEM 57 samalizumab 57 OHR/AVR# 57 preclinical efficacy 57 Corlux 57 Stedivaze 57 Bendavia 57 AZILECT R 57 QLT# 57 temsirolimus 57 potent antitumor activity 57 tezampanel NGX# 57 Vilazodone 57 aclidinium 57 SARMs 57 Pixantrone 57 Gemzar ® 57 bortezomib 57 EGFR inhibitors 57 TKM ApoB 57 Kevetrin 56 dasatinib Sprycel ® 56 Hematide 56 ARQ 56 Genasense ® 56 Phenserine 56 Elagolix 56 TRC# 56 #D#C# 56 recurrent glioblastoma 56 MB# [004] 56 ONTAK 56 CTAP# Capsules 56 ZACTIMA 56 mitogen activated ERK kinase 56 CD# monoclonal antibody 56 paclitaxel carboplatin 56 immunomodulator 56 CCR5 antagonist 56 novel histone deacetylase 56 Desmoteplase 56 Cimzia TM 56 visilizumab 56 DXL# 56 PRTX 56 telbivudine 56 leading oral taxane 56 Herceptin trastuzumab 56 trodusquemine 56 DG# [001] 56 PREOS 56 GAMMAGARD 56 rFIXFc 56 ALD# 56 Nexavar ® 56 AS# amonafide L malate 56 Ipilimumab 56 immunomodulatory therapy 56 FOLFOX6 56 IMP# 56 AZX# 56 Panitumumab 56 sorafenib 56 darinaparsin 56 Phase IIb trial 56 AACR NCI EORTC 56 GSK# [001] 56 KNS # 56 platinum refractory 56 vivo efficacy 56 nitazoxanide 56 ONCONASE 56 Phase II 56 TMC# [002] 56 abiraterone acetate 56 TYKERB 56 S/GSK# 56 LHRH antagonist 56 Erlotinib 56 antiviral activity 56 ERBITUX 56 sunitinib 56 NEUVENGE 56 HCV 56 Clolar ® 56 ATryn R 56 advanced NSCLC 56 BAL# [002] 56 selective kinase inhibitor 56 talabostat 56 pazopanib 56 ALK inhibitor 56 Revimmune 56 Ixempra 56 docetaxel 56 mRCC 56 motesanib 56 confirmatory Phase 3 56 afatinib 56 CRLX# 56 denufosol 56 combinability 56 NEUMUNE 56 preclinical models 56 Rituximab 56 iniparib 56 Canvaxin 56 Actilon 56 metastatic RCC 56 rituximab 56 investigational immunotherapy 56 Ostarine 56 MLN# 56 Rexin G 56 Cloretazine 56 AKT inhibitor 56 XL# SAR# 56 ITMN 56 resminostat 56 FOLFIRI 56 GED aPC 56 regorafenib 56 EGS# 56 Gemcitabine 56 drug conjugate 56 refractory chronic lymphocytic 56 ARIKACE 56 pegylated liposomal doxorubicin 56 diabetic nephropathy 56 muraglitazar 56 histone deacetylase inhibitor 56 SCCHN 56 MGd 56 Menerba 56 alkylating agent 56 candidate CRLX# 56 ZEVALIN 56 HCV protease 56 refractory gout 56 Talabostat 56 phase IIb study 56 SinuNase 56 Taxotere ® 56 lesinurad 56 MNTX 56 cetuximab Erbitux ® 56 bevacizumab Avastin ® 56 INT# [002] 56 LymphoStat B belimumab 56 Pazopanib 56 ATL# [001] 56 fostamatinib 56 Hedgehog Pathway Inhibitor 56 ProLindac 56 Catena ® 56 alvimopan 56 Alocrest 56 PD LID 56 MBP# [001] 56 PCK# 56 CTCE 56 cetuximab Erbitux 56 Zolinza 56 mitomycin 56 BENLYSTA 56 ALKS 56 R roscovitine 56 RhuDex ® 56 ZOLINZA 56 TRISENOX 56 SU# [003] 56 CLORETAZINE TM VNP#M 56 TriRima 56 REVLIMID 56 MetMAb 56 PANVAC VF 56 lorvotuzumab mertansine 56 Cetrorelix 56 ostarine 56 ZK EPO 56 Revlimid lenalidomide 56 investigational oral 56 Valortim 56 Trastuzumab 56 LY# [003] 56 UPLYSO 56 CD3 monoclonal antibody 56 BENLYSTA ® 56 Leukine 56 viral kinetic 56 TASQ 56 CD# CEA 56 Tarvacin TM 56 MultiStem 56 CRx 56 bevacizumab Avastin 56 zalutumumab 56 imatinib Gleevec ® 56 FavId 56 androgen independent 56 DASISION 56 renin inhibitor 56 Pivotal Phase 56 PrevOnco ™ 56 gemcitabine 56 dose escalation clinical 56 Vicriviroc 56 apremilast 56 randomized controlled Phase 56 LUX Lung 56 BEXXAR 56 metastatic HRPC 56 Motesanib 56 Ceflatonin R 56 antiangiogenic therapy 56 ara C 56 cabozantinib 56 LEP ETU 56 Radezolid 56 Entereg R 56 Tasimelteon 56 relapsed SCLC 56 APPRAISE 56 lupus nephritis 56 hematological cancers 56 Initiate Phase 55 anti EGFR antibody 55 metastatic colorectal cancer 55 CCR2 55 tolerability profile 55 paclitaxel Taxol ® 55 oral proteasome inhibitor 55 XYOTAX 55 IPLEX 55 Solazed 55 methylnaltrexone 55 JAK3 55 CCX# B 55 Aeroquin 55 Uvidem 55 bazedoxifene 55 ataluren 55 MYDICAR 55 vilazodone 55 Vicinium TM 55 PEP# [003] 55 Antiviral Activity 55 hypoxia activated prodrug 55 E1 INT TM 55 GLPG# 55 posaconazole 55 Phase #/#a trial 55 satraplatin Phase 55 MabCampath 55 MT# [002] 55 RAD# [003] 55 Pivotal Phase III 55 Xeloda ® 55 multi kinase inhibitor 55 metastatic castration resistant 55 PrevOnco 55 confirmatory Phase III 55 IAP inhibitors 55 TLR8 agonist 55 betrixaban 55 Ceplene/IL-2 55 Atu# 55 Phase IIa clinical trials 55 ONX 55 RSD# 55 Sorafenib 55 Æterna Zentaris 55 assessing T DM1 55 Celgosivir 55 TASKi2 55 systemically administered 55 Syncria 55 mCRC 55 multiple myeloma MM 55 BR.# 55 CCR9 antagonist 55 LEUKINE 55 pharmacokinetic profile 55 sodium glucose cotransporter 55 VEGFR2 inhibitor 55 CB# [002] 55 IND enabling 55 galiximab 55 mGluR5 negative 55 Telintra 55 compound INCB# 55 sodium thiosulfate STS 55 blinded randomized placebo controlled 55 apaziquone 55 Tesetaxel 55 JAK inhibitors 55 PF # [002] 55 Preclinical studies 55 GW# [003] 55 PARP inhibitors 55 dextromethorphan quinidine 55 PROSTVAC ® 55 ORENCIA ® 55 TMC# [001] 55 danoprevir 55 carboplatin paclitaxel 55 plus gemcitabine 55 TRV# [001] 55 Seliciclib 55 Allovectin 7 R 55 hepatocellular carcinoma 55 cell lymphoma CTCL 55 alpha#beta# integrin 55 Acetavance 55 LibiGel Phase III 55 JAK2 55 Civacir 55 GFT# 55 Taxotere R 55 unique alkylating agent 55 RITUXAN 55 Darinaparsin 55 Hsp# inhibitors 55 brentuximab vedotin SGN 55 pivotal Phase 55 ORENCIA R 55 urocortin 2 55 DR Cysteamine 55 GetGoal Phase III 55 taxane 55 ARC# [001] 55 IAP inhibitor 55 pharmacokinetic PK study 55 Luveniq 55 vismodegib 55 Pemetrexed 55 proteasome inhibitor bortezomib 55 Octreotide 55 lymphoma CTCL 55 Vandetanib 55 OMP #M# 55 xenograft models 55 tremelimumab 55 alagebrium 55 Avastin bevacizumab 55 Fibrillex TM 55 relapsed refractory 55 evaluating satraplatin 55 Anticalin 55 DEB# 55 GSK # 55 isoform selective 55 metastatic hormone refractory 55 PROVENGE 55 tolerated dose MTD 55 LBH# 55 Zenvia Phase III 55 BLA filing 55 VEGFR2 55 teplizumab 55 GRNVAC1 55 PRECISE trial 55 SPP# [001] 55 ipilimumab 55 HIV integrase inhibitor 55 Chrysalin 55 L Annamycin 55 VELCADE melphalan 55 oral gallium 55 metastatic CRC 55 PROSTVAC TM 55 pediatric acute lymphoblastic 55 GvHD 55 multicenter Phase II 55 Phase 2a Clinical Trial 55 bortezomib Velcade ® 55 lapatinib Tykerb 55 mg kg dose 55 omacetaxine mepesuccinate 55 Ceplene 55 GA# [003] 55 TRX1 55 Aptivus ® 55 Tocosol Paclitaxel 55 dosing cohort 55 indolent NHL 55 brivaracetam 55 BiTE 55 Erbitux cetuximab 55 Huntexil 55 Miraxion 55 demonstrated antitumor activity 55 cediranib 55 heavily pretreated 55 Ofatumumab 55 C1 INH 55 refractory NSCLC 55 TOLAMBA 55 Cloretazine R 55 gefitinib Iressa 55 humanized antibody 55 pegloticase 55 novel anticancer 55 dacarbazine DTIC 55 ARRY # 55 MET RET 55 lintuzumab SGN 55 opioid induced bowel dysfunction 55 cetuximab Erbitux R 55 cethromycin 55 XMT 55 OvaRex ® MAb 55 CTA# Injection 55 maximally tolerated dose